Evidence map›Paper›PMID 26528440›Full record

ReviewFrontiers in oncology2015

Ionizing Particle Radiation as a Modulator of Endogenous Bone Marrow Cell Reprogramming: Implications for Hematological Cancers.

Sujatha Muralidharan, Sharath P Sasi, Maria A Zuriaga, Karen K Hirschi, Christopher D Porada, Matthew A Coleman, Kenneth X Walsh, Xinhua Yan, David A Goukassian

Erratum issuedOpen access · goldAbstract readReview
In one paragraph

Review in Frontiers in oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Targeted Reduction of Senescent Cell Burden Alleviates Focal Radiotherapy-Related Bone Loss.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2020
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 1 country.

Sujatha MuralidharanWhitaker Cardiovascular Institute, Boston University School of Medicine , Boston, MA , USA.
Sharath P SasiCardiovascular Research Center, GeneSys Research Institute , Boston, MA , USA.
Maria A ZuriagaWhitaker Cardiovascular Institute, Boston University School of Medicine , Boston, MA , USA.
Karen K HirschiYale Cardiovascular Research Center, Yale School of Medicine , New Haven, CT , USA.
Christopher D PoradaWake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine , Winston-Salem, NC , USA.
Matthew A ColemanRadiation Oncology, School of Medicine, University of California Davis , Sacramento, CA , USA ; Lawrence Livermore National Laboratory , Livermore, CA , USA.
Kenneth X WalshWhitaker Cardiovascular Institute, Boston University School of Medicine , Boston, MA , USA.
Xinhua YanCardiovascular Research Center, GeneSys Research Institute , Boston, MA , USA ; Tufts University School of Medicine , Boston, MA , USA.
David A GoukassianWhitaker Cardiovascular Institute, Boston University School of Medicine , Boston, MA , USA ; Cardiovascular Research Center, GeneSys Research Institute , Boston, MA , USA ; Tufts University School of Medicine , Boston, MA , USA.
Boston University · USGenesys (United States) · USForest Institute · USTufts University · USUniversity of California, Davis · USYale University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Exposure of individuals to ionizing radiation (IR), as in the case of astronauts exploring space or radiotherapy cancer patients, increases their risk of developing secondary cancers and other health-related problems. Bone marrow (BM), the site in the body where hematopoietic stem cell (HSC) self-renewal and differentiation to mature blood cells occurs, is extremely sensitive to low-dose IR, including irradiation by high-charge and high-energy particles. Low-dose IR induces DNA damage and persistent oxidative stress in the BM hematopoietic cells. Inefficient DNA repair processes in HSC and early hematopoietic progenitors can lead to an accumulation of mutations whereas long-lasting oxidative stress can impair hematopoiesis itself, thereby causing long-term damage to hematopoietic cells in the BM niche. We report here that low-dose (1)H- and (56)Fe-IR significantly decreased the hematopoietic early and late multipotent progenitor (E- and L-MPP, respectively) cell numbers in mouse BM over a period of up to 10 months after exposure. Both (1)H- and (56)Fe-IR increased the expression of pluripotent stem cell markers Sox2, Nanog, and Oct4 in L-MPPs and 10 months post-IR exposure. We postulate that low doses of (1)H- and (56)Fe-IR may induce endogenous cellular reprogramming of BM hematopoietic progenitor cells to assume a more primitive pluripotent phenotype and that IR-induced oxidative DNA damage may lead to mutations in these BM progenitors. This could then be propagated to successive cell lineages. Persistent impairment of BM progenitor cell populations can disrupt hematopoietic homeostasis and lead to hematologic disorders, and these findings warrant further mechanistic studies into the effects of low-dose IR on the functional capacity of BM-derived hematopoietic cells including their self-renewal and pluripotency.

Indexed as

endogenous reprogramminghematological cancerHSCprogenitorsradiation

Identifiers

PMID26528440
PMCPMC4604322
OpenAlexW2167276353

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.